Background: Although perioperative chemotherapy for esophagogastric adenocarcinoma (ADC) improves survival, the overall poor prognosis suggests that further refinement of treatment is required. Docetaxel, cisplatin, and 5-fluorouracil (5-FU) (DCF) is effective for metastatic ADC of the upper gastrointestinal (GI) tract; we thus sought to investigate the efficacy of this regimen in patients with resectable disease. three cycles before and after resection. Primary end point was complete resection; secondary end points were response, toxicity, surgical morbidity, and overall survival.
introduction
Although resection remains the cornerstone of treatment with curative intent for adenocarcinoma (ADC) of the esophagus and stomach, surgery alone is associated with poor long-term outcomes with a 5-year survival of 25%-35% [1] [2] [3] [4] . Adjuvant chemoradiotherapy after resection of ADC of the stomach and gastroesophageal junction (GEJ) has been shown to increase disease-free and overall survival (OS) [5] ; however, this approach is associated with significant toxicity and was designed for patients who had undergone a complete resection. Unfortunately, in most surgical series of upper gastrointestinal cancer surgery, complete resection (R0) is achieved in only 65%-75% of patients [1, 6, 7] . An alternative adjuvant approach is perioperative chemotherapy without radiation therapy. In the MAGIC trial, perioperative epirubicin, cisplatin, and 5-fluorouracil (5-FU) (ECF) established a new standard of care for ADC of the upper gastrointestinal (GI) tract [8] . Over 25% of enrolled patients had distal esophageal and GEJ cancers. In this study, perioperative ECF resulted in downstaging of the tumor, increased complete resection rate, and a 13% increase in OS at 5 years. Furthermore, with neoadjuvant therapy, tolerability was acceptable and over 90% completed all three preoperative cycles.
Despite these encouraging results with perioperative chemotherapy, there is still room for improvement as over 65% of patients died of recurrent disease in the MAGIC trial at 5 years. This has led to the search for a more effective chemotherapy regimen to be employed in the neoadjuvant setting. In a comparison of DCF (docetaxel, cisplatin, 5-FU) versus CF as first-line therapy in advanced gastric cancer, the V325 trial demonstrated a higher response rate, time to progression, and OS in the docetaxel-containing arm. Despite concerns regarding toxicity, this trial thus established docetaxel-based combination chemotherapy as an active regimen in the metastatic setting [9] . Given this positive finding of DCF, we sought to investigate the efficacy and toxicity of perioperative DCF for patients with ADC of the foregut in a phase II multicenter trial. Ib (T1N1 only), II, IIIA, IIIB, and IV  (T4N1 only) were included]. Participants had adequate organ and hematologic reserve, a performance status of zero or one, and a life expectancy of at least 3 months. The primary aim was to determine the complete resection rate. Screening evaluation included computed tomography (CT) chest/abdomen/pelvis, positron emission tomography (PET) scan, and endoscopic ultrasound. Diagnostic laparoscopy with peritoneal lavage for cytology assessment was carried out in all gastric and type III EGJ tumor to rule out peritoneal involvement. Toxicity was graded according to National Cancer Institute-Common Toxicity Criteria (CTC) Version 3.0. 5-FU was dose reduced by 25% at any time for CTC grade 3 or greater diarrhea or mucositis and CTC grade 2 or greater hand and foot syndrome. Administration of cisplatin, docetaxel, and 5-FU was delayed as long as there was diarrhea or mucositis of CTC grade 2 or greater, neutropenia <1500/ll or thrombocytopenia <75 000/ll. Cisplatin was dose reduced by 50% for decreased creatinine clearance to 50-60 ml/min and was discontinued if <50 ml/min. Docetaxel was reduced by 25% in case of CTC grade 4 neutropenia persisting longer than 7 days or accompanied by fever and thrombocytopenia of CTC grade 3 or greater. Docetaxel was discontinued in the case of a severe hypersensitivity reaction or bilirubin level more than 2· upper limit of normal. Any drug was discontinued in the event of a delay by >2 weeks due to drug-specific toxicity. The patient was referred for surgery upon recovery, if treatment was prematurely discontinued in the preoperative phase.
Patients were restaged at the completion of chemotherapy with both a dedicated CT chest/abdomen/pelvis and a PET scan 4-5 weeks after the end of the last neoadjuvant chemotherapy cycle. Patients without distant metastases on restaging diagnostic imaging underwent resection 1-2 weeks later. Surgical approach was dictated by tumor location and patient performance status. Extended celiac lymphadenectomy (D2 dissection) and en bloc mediastinal dissection were recommended where applicable. Postoperative chemotherapy was commenced 6-12 weeks after surgical resection.
objectives and evaluation
The primary end point was R0 resection rate and secondary end points were response (pathological, radiographic, and metabolic) to chemotherapy, chemotherapy-related toxicity, surgical morbidity, OS, and disease-free survival. Radiographic response of hollow viscus organs is difficult to assess with RECIST criteria; thus, we evaluated radiographic response by changes in length or width of the primary tumor. Metabolic response was determined by the change in maximal standard uptake value (max SUV) in the primary. Tumor regression of the primary tumor was determined by the amount of viable tumor versus the amount of fibrosis, ranging from no evidence of any treatment effect to a complete response with no viable tumor identified, as previously described [10] . Proximal, distal, and circumferential margins were assessed to determine the completeness of resection. The absence of tumor cells at all three of these margins was required for an R0 resection. OS and disease-free survival are measured from the time of histological diagnosis. Postoperative morbidity was classified according to the scale proposed by Clavien [11] . Patients were followed every 3 months after surgery with clinical exam and CT chest/ abdomen/pelvis for the first 2 years. Follow-up and imaging were every 6 months in the third, forth, and fifth years and then yearly thereafter. Upper endoscopic evaluation took place at 6 and 12 months postoperatively and then on a yearly basis.
statistical analysis
This study was designed to detect a 20% improvement in complete resection rate from 65% to 85% with perioperative chemotherapy, based on published surgical experience with gastric and GEJ tumors [7] . Patient enrollment followed a two-stage sequential design [12] with an alpha level of 0.05 and power of 0.8. Accrual was to be halted if fewer than 11 of the initial 14 assessable patients had complete resections. In the second stage, 19 additional patients were to be enrolled for a total target patient population of 33 patients. The treatment was to be considered active and worthy of additional investigation in this patient population at the end of the study if a complete resection was achieved in at least 25 of the total 33 assessable patients. The sample size number was inflated by 10% to a total of 37 patients to allow for ineligible cases. With Institutional Review Board approval, the study was extended to 43 patients given a late surge in accrual.
results
Between May 2007 and September 2009, we completed the target accrual to this study and 43 patients commenced preoperative chemotherapy. An interim analysis of the pathology results after 14 patients revealed that there were no incomplete resections; thus, the study was continued to the target sample size of 43 patients. Patients were predominantly male (90%) with a median age of 64 years (24-80 years) and performance status of zero or one (12/34) ( Table 1 ). The majority of tumors were located within the distal esophagus or GEJ with seven (16%) centered in the gastric body or antrum. The majority of tumors were cT3/T4 (84%) and cN+ (79%).
chemotherapy
Chemotherapy was started in all 43 patients, 41 (95%) and 37 (87%) completed the second and third preoperative cycles, respectively. Major toxicity (grade 3/4) was present in 20/43 (47%) during the preoperative phase of the study consisting primarily of neutropenia and mucositis (Table 2) . Febrile neutropenia occurred in one patient in the preoperative phase. Postoperative chemotherapy was started in 29 patients (67%) and completed (six cycles) in 24 (56%). Reasons for not proceeding with the postoperative chemotherapy after completing three cycles of preoperative chemotherapy included patient choice (two patients), postoperative complications (two patients), and disease progression (four patients). After surgery, the chemotherapy regimen was tolerated with a lower rate of major toxicity than the preoperative phase (28% versus 47%).
surgery Surgery was carried out in 41 (95%) patients. One patient refused surgery and was administered radical, curative intent, chemoradiotherapy (cisplatin/5-FU + 50.4 Gy) after completing one cycle of chemotherapy on protocol. One additional patient had disease progression with a new vertebral body metastasis, identified on preoperative staging investigations. Due to a transfer of care to a nonparticipating institution, one of the resected patients was taken off protocol after three cycles of DCF and treated with an additional neoadjuvant regimen of chemoradiotherapy (cisplatin/5-FU + 50.4 Gy) before surgery. Tumor location and patient performance status greatly dictated surgical approach and a variety of surgical techniques were employed (Table 3) . A transthoracic, en bloc two-field resection (30/41) with extended (D2) celiac lymph node dissection was most frequent. Postoperative complications were present in 16 patients (39%); however, the majority of these were minor (Clavien grade 1-2) ( Table 3) . Major complications (Clavien grade 3-5) arose in only four patients (10%) with three anastomotic leaks and one acute lung herniation [13] . There was no surgical mortality. Baseline and preoperative PET scans were available in 33 patients (77%). Ten patients did not have preoperative PET scans, six of which had signet-ring cell ADC primary tumors that were not FDG avid at baseline; thus, a repeat PET was not carried out. Administrative error in the timing of the preoperative PET scan resulted in four patients not undergoing this test before surgery. Overall, max SUV of the primary tumor was reduced by over 50% (13.3-5.4 ) with preoperative chemotherapy. The vast majority of patients had a reduction in max SUV (29/33) , and almost 80% (25/33) had a reduction in max SUV >35%, a value that has been proposed to be clinically significant [14] . A complete resolution of metabolic activity was seen in three patients.
pathological findings
Pathological assessment of the 41 surgical specimens revealed a tumor size of 4 (0-10) cm, the majority of which were ypT3 (Table 4) , and moderately to poorly differentiated. Intraoperative assessment (frozen section) of surgical margins (proximal and distal) was obtained in most patients, and final assessment of margins (proximal, distal, and circumferential) on formalin-fixed tissue revealed complete resection (R0) in all 41 patients (100%). Extended lymphadenectomy yielded 35 (11-73) lymph nodes. At least 15 lymph nodes, widely accepted as the minimum number to adequately stage gastric and esophageal cancers [15] , were retrieved in 38/41 (93%) of patients. At least 1 positive lymph node was found in 28/41 (68%) with an average of 7 (1-29) positive lymph nodes in these patients (Table 4) .
Pathological response was determined using a modification of the method proposed by Becker et al. [10] in which the proportion of viable tumor is compared with the microscopically confirmed tumor scar. Complete pathological response (no viable tumor cells) was achieved in 4/41 (10%) patients. A good partial response (>50% tumor regression) was seen in 16/41 (39%) patients, and a moderate partial response (25-50% tumor regression) in 11/41 (27%). 
discussion
In this multi-institutional phase II trial investigating perioperative chemotherapy in the treatment of locally advanced ADC of the upper GI tract, we demonstrate that combination DCF is not only a tolerable but also a highly efficacious regimen.
The superiority of adding ECF to surgery alone in the MAGIC trial established perioperative chemotherapy as a standard of care [8, 16] . Compared with MAGIC in which 74% of patients had gastric cancer, 84% of patients in this study had lower esophageal or GEJ ADCs. More recently, a phase III perioperative trial (FFCD 9703) using a simpler regimen of 5-FU and cisplatin alone reported a significant and similar survival benefit to MAGIC in a similar population to this study (75% lower esophageal or GEJ cancer) [17] .
Disadvantages of ECF include anthracycline-induced cardiotoxicity and a lengthy 21-day continuous infusion of 5-FU at each cycle. The addition of docetaxel to the combination of cisplatin and shorter duration continuous infusion 5-FU in V325 has yielded superior results in the metastatic setting [16] ; however, the DCF combination has been considered by some to be a toxic regimen due to high rates of myelosuppression. In V325, a 30-day mortality rate of 10% was reported in the DCF arm thought to be closely associated to the high rate of severe neutropenia (grade 3-4 = 82%). This contrasts significantly with the grade 3-4 neutropenia rate of 15% we report here, as well as a febrile neutropenia rate of 2.5% and no treatment-related mortality. Furthermore, this low rate of high-grade neutropenia compares favorably to that induced by preoperative ECF (23%) and CF (20.2%) in the MAGIC and FFCD 9703 trials, respectively. This improvement is likely attributable to the routine use of primary 
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prophylaxis with granulocyte colony-stimulating factor combined with a target population without metastatic disease. Significant mucosal toxicity (grade 3-4) was seen in 14% of patients in the preoperative phase, less than that published in the V325 trial (21%) but more with ECF in the MAGIC (4.3%). This important difference in mucosal toxicity is secondary to the dose and schedule of 5-FU in the two regimens: 750 mg/m 2 /day for 5 days with DCF and 200 mg/m 2 /day for 21 days with ECF. Mucosal toxicity encountered by the patients receiving DCF in this present study was counterbalanced in part by a marked early improvement in dysphagia and quality of life [18] .
The primary outcome of this present study was complete (R0) resection. Indeed, we were able to achieve negative margins (proximal, distal, and circumferential) in all 41 patients undergoing resection. This number is significantly higher than that published in other surgical series citing a rate between 54% and 91% [6, [19] [20] [21] [22] [23] . Neoadjuvant therapy has been shown to increase the R0 resection rate, but our ability to achieve complete resection in all patients is still greater than most other neoadjuvant therapy trials [8, 19, 23, 24] . Other than the chemotherapy regimen employed in this study, other possible reasons for the high rate of complete resection include the intensive staging investigations required before enrollment limiting the inclusion of patients with occult metastases, the high rate of en bloc resections, and performance of nearly all resections by a single experienced thoracic surgical oncologist in a high volume center.
Response, measured by radiographic or metabolic methods, occurred in the majority of patients. Using a change in tomographic tumor length or width as previously described [25, 26] , we have shown a reduction in tumor metrics after chemotherapy in 89% of patients. Although the correlation of PET response with histopathologic response is controversial [14, [27] [28] [29] , we nonetheless found a large number of patients (25/33 = 76%) in whom the max SUV decreased by over 35%, a value perceived to be clinically relevant [14, 25] . We also demonstrated that over 50% tumor regression was present in half of the resected specimen (20/41). Pathologic complete response (pCR) was achieved in 10% (4/41) of assessable patients, a rate that compares favorably with that reported using other chemotherapy regimens without radiotherapy. Stahl et al. [24] , in a study comparing chemotherapy versus chemoradiotherapy for a similar patient population, report a pCR rate of 2% with regimen consisting of cisplatin, 5-FU, and leucovorin [24] . Using a simpler regimen of cisplatin and 5-FU, both the OEO2 and FFCD trials revealed a pCR rate of 4% and 3%, respectively [17, 23] .
Postoperative complications arose in 16/41 (39%), the majority of which were minor. This compares favorably to the rate of surgical morbidity reported by other surgical series in the literature ranging from 40% to 60% [2, 6, 30, 31] . In particular, the anastomotic leak rate was 7%, on the lower end of the published rate for upper GI surgery [6, 31] . The addition of neoadjuvant therapy did not result in a greater rate of postoperative complications compared with these previous series. Reports of increased morbidity after neoadjuvant treatment likely are related to the addition of radiation to chemotherapy [24, 32] . Extended celiac lymphadenectomy (D2-in 85% of cases) was not associated with an increased complication rate when compared with the literature. Although results from a randomized Dutch trial examining extended lymph node dissection for gastric cancer surgery [4] demonstrated a higher complication rate compared with less extensive surgery, we have shown, as have others [33] , that these procedures can be carried out safely in a high volume center. These extended resections yielded over 35 lymph nodes, a number exceeding the minimum required for adequate staging.
In conclusion, perioperative docetaxel, ciplatin, and 5-FU in patients with locally advanced ADC of the foregut is a safe, tolerable and highly efficacious option. Although longer-term survival data are pending, these initial data give support to the further study of perioperative DCF for resectable gastric, GEJ, or lower esophageal ADC, either as a standalone regimen or in combination with a biologic agent. Recent modification of this combination in the metastatic setting may render it more tolerable and acceptable as an alternative to standard perioperative ECF [34] .
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